Gender Differences in the Diagnosis and Treatment of HIVSQUIRES, Kathleen E.Gender medicine. 2007, Vol 4, Num 4, pp 294-307, issn 1550-8579, 14 p.Article

An introduction to nucleoside and nucleotide analoguesSQUIRES, Kathleen E.Antiviral therapy (London). 2001, Vol 6, pp 1-14, issn 1359-6535, SUP3Conference Paper

Bone Health and Human Immunodeficiency Virus InfectionSCHAFER, Jason J; MANLANGIT, Kristine; SQUIRES, Kathleen E et al.Pharmacotherapy. 2013, Vol 33, Num 6, pp 665-682, issn 0277-0008, 18 p.Article

Integrase Inhibitors: A Novel Class of Antiretroviral AgentsSCHAFER, Jason J; SQUIRES, Kathleen E.The Annals of pharmacotherapy. 2010, Vol 44, Num 1, pp 145-156, issn 1060-0280, 12 p.Article

Association Between Abacavir Exposure and Increased Risk for Cardiovascular Disease in Patients with Human Immunodeficiency VirusSCHAFER, Jason J; SHORT, William R; SQUIRES, Kathleen E et al.Pharmacotherapy. 2010, Vol 30, Num 10, pp 1072-1083, issn 0277-0008, 12 p.Article

Cobicistat: A New Boost for the Treatment of Human Immunodeficiency Virus InfectionSHAH, Bhavik M; SCHAFER, Jason J; PRIANO, James et al.Pharmacotherapy. 2013, Vol 33, Num 10, pp 1107-1116, issn 0277-0008, 10 p.Article

Prevalence and Risk Factors for HPV in HIV-Positive Young Women Receiving Their First HPV VaccinationKAHN, Jessica A; BURK, Robert D; SQUIRES, Kathleen E et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 61, Num 3, pp 390-399, issn 1525-4135, 10 p.Article

Plasma HiV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens : ACTG A5166s. CommentaryMARKOWITZ, Martin; PERELSON, Alan S; MEYER, William A et al.The Journal of infectious diseases. 2007, Vol 195, Num 8, issn 0022-1899, 1087-1088,1169-1176 [10 p.]Article

Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppressionGULICK, Roy M; LALAMA, Christina M; KLINGMAN, Karin L et al.AIDS (London). 2007, Vol 21, Num 7, pp 813-823, issn 0269-9370, 11 p.Article

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection : A randomized controlled trialGULICK, Roy M; RIBAUDO, Heather J; MURPHY, Robert L et al.JAMA, the journal of the American Medical Association. 2006, Vol 296, Num 7, pp 769-781, issn 0098-7484, 13 p.Article

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infectionGULICK, Roy M; RIBAUDO, Heather J; MAHER, William E et al.The New England journal of medicine. 2004, Vol 350, Num 18, pp 1850-1861, issn 0028-4793, 12 p.Article

Once-daily quadruple-drug therapy with adefovir dipivoxil, lamivudine, didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patientsSKOWRON, Gail; KURITZKES, Daniel R; THOMPSON, Melanie A et al.The Journal of infectious diseases. 2002, Vol 186, Num 7, pp 1028-1033, issn 0022-1899, 6 p.Article

Prevalence of obstructive lung disease in HIV population: A cross sectional studyHIRANI, Amyn; CAVALLAZZI, Rodrigo; KANE, Gregory C et al.Respiratory medicine. 2011, Vol 105, Num 11, pp 1655-1661, issn 0954-6111, 7 p.Article

Prevalence and Persistence of Cervical Human Papillomavirus Infection in HIV-Positive Women Initiating Highly Active Antiretroviral TherapyFIFE, Kenneth H; WU, Julia W; SQUIRES, Kathleen E et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 51, Num 3, pp 274-282, issn 1525-4135, 9 p.Article

Comparative analysis of commercial assays for the detection and quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma from patients infected with HIV-1 subtype CHOESLEY, Craig J; ALIEN, Susan A; RAPER, James L et al.Clinical infectious diseases. 2002, Vol 35, Num 3, pp 323-325, issn 1058-4838Article

Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: Safety, pharmacokinetics, and antiretroviral activityRIDDLER, Sharon A; HAVLIR, Diane; SAAH, Alfred et al.Antimicrobial agents and chemotherapy. 2002, Vol 46, Num 12, pp 3877-3882, issn 0066-4804, 6 p.Article

Immunogenicity and Safety of the Human Papillomavirus 6, 11, 16, 18 Vaccine in HIV-Infected Young WomenKAHN, Jessica A; JIAHONG XU; KAPOGIANNIS, Bill G et al.Clinical infectious diseases. 2013, Vol 57, Num 5, pp 735-744, issn 1058-4838, 10 p.Article

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patientsSQUIRES, Kathleen E; YOUNG, Benjamin; DEJESUS, Edwin et al.AIDS (London). 2010, Vol 24, Num 13, pp 2019-2027, issn 0269-9370, 9 p.Article

Incidence and risk factors for sexually transmitted infections among women in an alabama HIV clinicMONTEIRO, Cheryl-Ann; BACHMANN, Laura H; DESMOND, Renee A et al.AIDS research and human retroviruses. 2004, Vol 20, Num 6, pp 577-583, issn 0889-2229, 7 p.Article

A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: Correlations with CD4 cell count and plasma HIV-1 RNA levelWRIGHT, Patty W; HOESLEY, Craig J; SQUIRES, Kathleen E et al.Clinical infectious diseases. 2003, Vol 36, Num 2, pp 207-211, issn 1058-4838, 5 p.Article

A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavirHAMMER, Scott M; BASSETT, Roland; DEGRUTTOLA, Victor et al.Antiviral therapy (London). 2003, Vol 8, Num 6, pp 507-518, issn 1359-6535, 12 p.Article

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and topinavir/ritonavir at 96 weeks in the CASTLE studySQUIRES, Kathleen E; JOHNSON, Margaret; RONG YANG et al.Journal of antimicrobial chemotherapy (Print). 2011, Vol 66, Num 2, pp 363-370, issn 0305-7453, 8 p.Article

HIV Policy: The Path Forward―A Joint Position Paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of PhysiciansLUBINSKI, Christine; ABERG, Judith; ZEREHI, M. Renee et al.Clinical infectious diseases. 2009, Vol 48, Num 10, pp 1335-1344, issn 1058-4838, 10 p.Article

Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4⁺ T-cell decline or improve other indices of immune function: Results of a randomized controlled Clinical trial (ACTG 248)VOGLER, Mary A; TEPPLER, Hedy; FRANK, Ian et al.Journal of acquired immune deficiency syndromes (1999). 2004, Vol 36, Num 1, pp 576-587, issn 1525-4135, 12 p.Article

Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjectsDICENZO, Robert; FORREST, Alan; SQUIRES, Kathleen E et al.Antimicrobial agents and chemotherapy. 2003, Vol 47, Num 6, pp 1929-1935, issn 0066-4804, 7 p.Article